blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1414471

EP1414471 - Therapeutic agents comprising pro-apoptotic proteins [Right-click to bookmark this link]
Former [2004/19]THERAPEUTIC AGENTS COMPRISING PRO-APOPTOTIC PROTEINS
[2012/03]
StatusNo opposition filed within time limit
Status updated on  19.04.2013
Database last updated on 05.10.2024
Most recent event   Tooltip30.05.2014Lapse of the patent in a contracting state
New state(s): LU		published on 02.07.2014  [2014/27]
Applicant(s)For all designated states
RESEARCH DEVELOPMENT FOUNDATION
402 North Division Street
Carson City, Nevada 89703 / US
[2012/24]
Former [2004/19]For all designated states
RESEARCH DEVELOPMENT FOUNDATION
402 North Division Street
Carson City, Nevada 89703 / US
Inventor(s)01 / ROSENBLUM, Michael, G.
3127 Stoney Mist Drive
Sugar Land, TX 77479 / US
02 / LIU, Yuying
4045 Linkwood Drive
Apt.331
Houston, TX 77025 / US
 [2012/24]
Former [2004/19]01 / ROSENBLUM, Michael, G.
3127 Stoney Mist Drive
Sugar Land, TX 77479 / US
02 / LIU, Yuying
4045 Linkwood Drive, Apt.331
Houston, TX 77025 / US
Representative(s)Campbell, Joanne Marie
Stevens, Hewlett & Perkins
1 St. Augustine's Place
Bristol BS1 4UD / GB
[N/P]
Former [2013/20]Heaton, Joanne Marie
Stevens, Hewlett & Perkins 1 St. Augustine's Place
Bristol BS1 4UD / GB
Former [2012/24]McQueen, Andrew Peter, et al
Stevens, Hewlett & Perkins 1 St. Augustine's Place
Bristol BS1 4UD / GB
Former [2005/21]McQueen, Andrew Peter, et al
Stevens, Hewlett & Perkins 1 St. Augustine's Place
Bristol BS1 4UD / GB
Former [2004/19]Wilkinson, Stephen John
Stevens, Hewlett & Perkins 1 St. Augustine's Place
Bristol BS1 4UD / GB
Application number, filing date02763328.817.07.2002
[2004/19]
WO2002US23378
Priority number, dateUS20010306091P17.07.2001         Original published format: US 306091 P
US20010332886P06.11.2001         Original published format: US 332886 P
US20020360361P28.02.2002         Original published format: US 360361 P
[2004/19]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO03007889
Date:30.01.2003
Language:EN
[2003/05]
Type: A2 Application without search report 
No.:EP1414471
Date:06.05.2004
Language:EN
The application published by WIPO in one of the EPO official languages on 30.01.2003 takes the place of the publication of the European patent application.
[2004/19]
Type: B1 Patent specification 
No.:EP1414471
Date:13.06.2012
Language:EN
[2012/24]
Search report(s)International search report - published on:US09.10.2003
(Supplementary) European search report - dispatched on:EP16.11.2005
ClassificationIPC:C12N15/62, C12N9/64, C07K14/47, A61P35/00
[2012/03]
CPC:
C12N9/6467 (EP,US); C07K14/52 (EP,KR,US); A61P1/00 (EP);
A61P1/04 (EP); A61P19/02 (EP); A61P27/02 (EP);
A61P29/00 (EP); A61P3/10 (EP); A61P31/00 (EP);
A61P35/00 (EP); A61P35/04 (EP); A61P43/00 (EP);
A61P9/10 (EP); C07K14/4747 (EP,US); C07K14/715 (KR);
C07K16/24 (KR); A61K38/00 (EP,US); C07K2319/00 (EP,US) (-)
Former IPC [2004/19]A61K31/70, C07H21/04, C12N15/12, C12P19/34
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE,   SK,   TR [2004/19]
TitleGerman:Therapeutische Mittel mit pro-apoptotischen Proteinen[2012/03]
English:Therapeutic agents comprising pro-apoptotic proteins[2012/03]
French:Agents thérapeutiques contenant des protéines pro-apoptotiques[2012/03]
Former [2004/19]THERAPEUTISCHE MITTEL MIT PRO-APOPTOTISCHEN PROTEINEN
Former [2004/19]THERAPEUTIC AGENTS COMPRISING PRO-APOPTOTIC PROTEINS
Former [2004/19]AGENTS THERAPEUTIQUES CONTENANT DES PROTEINES PRO-APOPTOTIQUES
Entry into regional phase16.01.2004National basic fee paid 
16.01.2004Search fee paid 
16.01.2004Designation fee(s) paid 
16.01.2004Examination fee paid 
Examination procedure12.02.2003Request for preliminary examination filed
International Preliminary Examining Authority: US
16.01.2004Examination requested  [2004/19]
18.03.2004Amendment by applicant (claims and/or description)
08.12.2008Despatch of a communication from the examining division (Time limit: M02)
30.01.2009Reply to a communication from the examining division
24.08.2009Despatch of a communication from the examining division (Time limit: M06)
05.02.2010Reply to a communication from the examining division
23.08.2010Despatch of a communication from the examining division (Time limit: M04)
30.12.2010Reply to a communication from the examining division
03.01.2012Communication of intention to grant the patent
26.04.2012Fee for grant paid
26.04.2012Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.12.2008
Opposition(s)14.03.2013No opposition filed within time limit [2013/21]
Fees paidRenewal fee
22.07.2004Renewal fee patent year 03
20.07.2005Renewal fee patent year 04
27.07.2006Renewal fee patent year 05
27.07.2007Renewal fee patent year 06
25.07.2008Renewal fee patent year 07
28.07.2009Renewal fee patent year 08
26.07.2010Renewal fee patent year 09
25.07.2011Renewal fee patent year 10
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT13.06.2012
BE13.06.2012
CY13.06.2012
CZ13.06.2012
EE13.06.2012
FI13.06.2012
IT13.06.2012
SK13.06.2012
TR13.06.2012
LU17.07.2012
MC31.07.2012
BG13.09.2012
GR14.09.2012
ES24.09.2012
PT15.10.2012
[2014/27]
Former [2014/21]AT13.06.2012
BE13.06.2012
CY13.06.2012
CZ13.06.2012
EE13.06.2012
FI13.06.2012
IT13.06.2012
SK13.06.2012
TR13.06.2012
MC31.07.2012
BG13.09.2012
GR14.09.2012
ES24.09.2012
PT15.10.2012
Former [2013/34]AT13.06.2012
BE13.06.2012
CY13.06.2012
CZ13.06.2012
EE13.06.2012
FI13.06.2012
IT13.06.2012
SK13.06.2012
MC31.07.2012
BG13.09.2012
GR14.09.2012
ES24.09.2012
PT15.10.2012
Former [2013/22]AT13.06.2012
BE13.06.2012
CY13.06.2012
CZ13.06.2012
EE13.06.2012
FI13.06.2012
IT13.06.2012
SK13.06.2012
MC31.07.2012
GR14.09.2012
ES24.09.2012
PT15.10.2012
Former [2013/13]AT13.06.2012
BE13.06.2012
CY13.06.2012
CZ13.06.2012
EE13.06.2012
FI13.06.2012
IT13.06.2012
SK13.06.2012
MC31.07.2012
GR14.09.2012
PT15.10.2012
Former [2013/11]AT13.06.2012
BE13.06.2012
CY13.06.2012
CZ13.06.2012
EE13.06.2012
FI13.06.2012
IT13.06.2012
SK13.06.2012
MC31.07.2012
GR14.09.2012
Former [2013/10]AT13.06.2012
BE13.06.2012
CY13.06.2012
CZ13.06.2012
EE13.06.2012
FI13.06.2012
SK13.06.2012
GR14.09.2012
Former [2013/09]AT13.06.2012
BE13.06.2012
CY13.06.2012
EE13.06.2012
FI13.06.2012
GR14.09.2012
Former [2013/07]AT13.06.2012
BE13.06.2012
CY13.06.2012
FI13.06.2012
GR14.09.2012
Former [2012/50]CY13.06.2012
FI13.06.2012
GR14.09.2012
Former [2012/49]CY13.06.2012
FI13.06.2012
Former [2012/48]FI13.06.2012
Documents cited:Search[XD]WO9746259  (YISSUM RES DEV CO [IL], et al) [XD] 1 * the whole document *;
 [X]WO9943840  (BOEHRINGER INGELHEIM PHARMA [US]) [X] 1-15,18,22-38,45-49,56,58,59 * page 28, line 6 *;
 [X]  - ARORA N ET AL, "Vascular endothelial growth factor chimeric toxin is highly active against endothelial cells", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, (19990101), vol. 59, ISSN 0008-5472, pages 183 - 188, XP002271436 [X] 1 * the whole document *
 [T]  - LIU YUYING ET AL, "Mechanistic studies of a novel human fusion toxin composed of vascular endothelial growth factor (VEGF)121 and the serine protease granzyme B: directed apoptotic events in vascular endothelial cells.", MOLECULAR CANCER THERAPEUTICS. OCT 2003, (200310), vol. 2, no. 10, ISSN 1535-7163, pages 949 - 959, XP002333236 [T] 1-40,45-51,56-59 * the whole document *
International search[X]WO9837901  (BOEHRINGER INGELHEIM PHARMA [US], et al)
ExaminationWO9945128
by applicant   - ZUNINO SJ; BLEACKLEY RC; MARTINEZ J; HUDIG D, "RNKP-1, a novel natural killer cell-associated serine protease gene cloned from RNK-16 cytotoxic lymphocytes", J IMMUNOL, (1990), vol. 144, pages 2001 - 2009
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.